01:34 PM EST, 12/24/2025 (MT Newswires) -- Biohaven ( BHVN ) said Wednesday the phase 2 study evaluating BHV-7000 for the treatment of major depressive disorder failed to meet its primary endpoint.

The proof-of-concept trial's main goal was the reduction of depressive symptoms as measured by change in the Montgomery Asberg Depression Rating Scale over six weeks compared with placebo, the company said, adding that the therapy was overall safe and well-tolerated.

The company also said that it does not plan further psychiatric trials, choosing instead to focus efforts on immunology, obesity, and epilepsy in 2026.

Shares of Biohaven ( BHVN ) fell over 16% in after hours trading Wednesday.

Price: 10.72, Change: +0.22, Percent Change: +2.10